Orlowski, R. Z., Moreau, P., Niesvizky, R., Ludwig, H., Oriol, A., Chng, W. J., . . . Dimopoulos, M. A. (2019). Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Updated overall survival, safety, and subgroups. Clinical lymphoma, myeloma & leukemia, 19(8), . https://doi.org/10.1016/j.clml.2019.04.018
Chicago-Zitierstil (17. Ausg.)Orlowski, Robert Z., et al. "Carfilzomib-dexamethasone Versus Bortezomib-dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups." Clinical Lymphoma, Myeloma & Leukemia 19, no. 8 (2019). https://doi.org/10.1016/j.clml.2019.04.018.
MLA-Zitierstil (9. Ausg.)Orlowski, Robert Z., et al. "Carfilzomib-dexamethasone Versus Bortezomib-dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups." Clinical Lymphoma, Myeloma & Leukemia, vol. 19, no. 8, 2019, https://doi.org/10.1016/j.clml.2019.04.018.